Calidi Biotherapeutics Files 8-K on Equity Sales
Ticker: CLDWW · Form: 8-K · Filed: Jul 29, 2024 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Jul 29, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $1.431, $1.90, $1,000,000, $2,000,000 b |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, definitive-agreement
Related Tickers: CLDI
TL;DR
Calidi Biotherapeutics filed an 8-K on July 26, 2024, regarding unregistered equity sales.
AI Summary
On July 26, 2024, Calidi Biotherapeutics, Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company, formerly known as First Light Acquisition Group, Inc. until April 6, 2021, is incorporated in Delaware and headquartered in San Diego, CA.
Why It Matters
This filing indicates potential new equity issuance, which could impact share dilution and the company's financial structure.
Risk Assessment
Risk Level: medium — Unregistered equity sales can sometimes signal financial distress or dilution concerns for existing shareholders.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- First Light Acquisition Group, Inc. (company) — Former company name
- July 26, 2024 (date) — Date of earliest event reported
- April 6, 2021 (date) — Date of name change
FAQ
What type of material definitive agreement was entered into by Calidi Biotherapeutics?
The filing indicates a material definitive agreement related to unregistered sales of equity securities.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on July 26, 2024.
What was Calidi Biotherapeutics' former company name?
Calidi Biotherapeutics, Inc. was formerly known as First Light Acquisition Group, Inc.
On what date did the company change its name?
The company's name change occurred on April 6, 2021.
In which state is Calidi Biotherapeutics incorporated?
Calidi Biotherapeutics, Inc. is incorporated in Delaware.
Filing Stats: 1,166 words · 5 min read · ~4 pages · Grade level 10.3 · Accepted 2024-07-29 09:15:16
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
- $1.431 — of Common Stock at a purchase price of $1.431 per share (90% of the per share closing
- $1.90 — he "Warrants"), at an exercise price of $1.90 (120% of the per share closing price of
- $1,000,000 — 24), for an aggregate purchase price of $1,000,000 (the "Private Placement"). The Warran
- $2,000,000 b — a strategic investment of approximately $2,000,000 by Dr. Rigor into Nova Cell, Inc., a Neva
Filing Documents
- form8-k.htm (8-K) — 58KB
- ex4-1.htm (EX-4.1) — 107KB
- ex10-2.htm (EX-10.2) — 9KB
- ex10-1.htm (EX-10.1) — 93KB
- ex10-3.htm (EX-10.3) — 26KB
- ex99-1.htm (EX-99.1) — 15KB
- ex4-1_001.jpg (GRAPHIC) — 5KB
- ex10-1_001.jpg (GRAPHIC) — 5KB
- ex10-2_001.jpg (GRAPHIC) — 391KB
- ex10-2_002.jpg (GRAPHIC) — 481KB
- ex10-2_003.jpg (GRAPHIC) — 460KB
- ex10-2_004.jpg (GRAPHIC) — 121KB
- ex10-2_005.jpg (GRAPHIC) — 93KB
- ex10-2_006.jpg (GRAPHIC) — 153KB
- ex10-2_007.jpg (GRAPHIC) — 27KB
- ex10-2_008.jpg (GRAPHIC) — 167KB
- ex10-2_009.jpg (GRAPHIC) — 618KB
- ex10-2_010.jpg (GRAPHIC) — 626KB
- ex10-2_011.jpg (GRAPHIC) — 450KB
- ex10-2_012.jpg (GRAPHIC) — 44KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-24-029384.txt ( ) — 5592KB
- cldi-20240726.xsd (EX-101.SCH) — 4KB
- cldi-20240726_def.xml (EX-101.DEF) — 26KB
- cldi-20240726_lab.xml (EX-101.LAB) — 36KB
- cldi-20240726_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: July 29, 2024 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer